The recombinant hCG study in older men separates a biological response from a functional benefit. Reporting only hormone or lean-mass changes would leave out a central part of its result. Primary trial
Trial findings
Forty men over 60 with partial age-related androgen deficiency were randomized to recombinant hCG or placebo for three months. Lean body mass and testosterone increased, while fat mass decreased. The study did not demonstrate significant improvements in measured strength, physical activity, gait, or balance. Testicular volume decreased, and three men developed nipple tenderness. All participants completed follow-up in the reported study. Primary trial
Our appraisal: body composition is not physical performance
Mass, strength, and the ability to carry out an activity are different endpoints. A body-composition change can be real without implying an improvement in every functional test. Conversely, a functional improvement would need its own estimate and uncertainty rather than borrowing credibility from a laboratory result.
For an illustrative example, imagine an intervention that increases a measured tissue compartment but leaves walking performance unchanged. The correct summary preserves both observations. It should neither hide the unchanged function nor deny the measured composition change.
Checks for a fuller review
We would inspect the body-composition method, strength-testing protocol, baseline functional capacity, precision, and handling of multiple outcomes. The timing of hormonal, body-composition, and functional assessments also belongs in the extraction table.
The study used a specified recombinant preparation in a selected population. Its findings do not establish equivalence for every material labeled hCG, and they do not answer all questions about younger people or other clinical indications. This record is a historical evidence appraisal, not a recommendation to manipulate hormone levels.
Frequently asked questions
Did a testosterone increase establish improved strength?
No. The measured strength outcomes did not show significant improvement.
Was lean mass the only relevant endpoint?
No. Function, activity, hormones, and adverse observations also matter.
Were men under 60 the target population?
No. The enrolled group was older than 60.
Was the preparation described as recombinant?
Yes. That identity should remain attached to the study.
Can this trial answer fertility-treatment questions?
Those require evidence matched to their own population and endpoints.
Does an unchanged functional test prove no biological action?
No. Different outcomes can show different patterns.
What remains before release?
Full-paper verification, complete safety appraisal, publication-history checking, and clear links to the broader hCG identity guide.